Newsroom | 5284 results

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company headquartered in Chicago and focused on the development and commercialization of generic injectable medicines, biologics, fertility products and branded medicines, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Garzulys™ (insulin aspart-fsan) injection, a biosimilar to NovoLog® (insulin aspart). Emerge Bioscience Pte. Ltd. (“Emerge”) is the holder...

CINCINNATI--(BUSINESS WIRE)--Resilience today announced it has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines....

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral candidates for obesity and obesity-related disorders, today announces that the first patient has been dosed in a Phase 1 SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity. The Phase 1 randomized, double-blind, placebo-controlled study wil...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark...

BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED, Inc., a clinical-stage pharmaceutical company developing TIX100 as a first-in-class oral inhibitor of thioredoxin-interacting protein (TXNIP) for diabetes and metabolic disease, today announced the appointment of Stephen E. Daly and Albert R. Collinson, Ph.D., to its Board of Directors. Both directors bring extensive experience in the development and commercialization of diabetes and metabolic-disease therapeutics, further strengthening the company’s...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Canaccord Genuity’s 46th Annual Growth Conference on Tuesday, August 11, 2026 at 1:30pm Eastern Time (10:30am Pacific Time). The presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care...

TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)--Longevity AI, a clinical intelligence company helping healthcare organizations deliver proactive, preventive care at scale, today announced a joint research collaboration with clinicians and researchers from Meir Medical Center of the Clalit Health Services Group. The research focuses on evaluating and refining clinical risk prediction models for cardiovascular disease and Type 2 diabetes, using longitudinal real-world data from Clalit’s integrated...

DENVER--(BUSINESS WIRE)--Virta Health, the leader in reversing metabolic disease, today announced new peer-reviewed research suggesting that one of healthcare's most devastating and expensive chronic diseases may be far more preventable, and reversible, than previously recognized. Published in Diabetes, Obesity and Metabolism, this was one of the largest real-world studies of nutrition-based metabolic care, tracking more than 10,000 patients over 5 years. The findings revealed adults with type...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated low density lipoprotein-cholesterol (LDL-C) and early onset cardiovascular disease. Arrowhe...

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom...